Ankit Mahadevia
2020
In 2020, Ankit Mahadevia earned a total compensation of $2.1M as Chief Executive Officer at Spero Therapeutics, a 19% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $424,049 |
|---|---|
| Option Awards | $1,153,962 |
| Salary | $536,667 |
| Other | $6,110 |
| Total | $2,120,788 |
Mahadevia received $1.2M in option awards, accounting for 54% of the total pay in 2020.
Mahadevia also received $424K in non-equity incentive plan, $536.7K in salary and $6.1K in other compensation.
Rankings
In 2020, Ankit Mahadevia's compensation ranked 5,252nd out of 13,090 executives tracked by ExecPay. In other words, Mahadevia earned more than 59.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,252 out of 13,090 | 60th |
Division Manufacturing | 2,163 out of 5,618 | 62nd |
Major group Chemicals And Allied Products | 866 out of 2,251 | 62nd |
Industry group Drugs | 745 out of 1,951 | 62nd |
Industry Pharmaceutical Preparations | 557 out of 1,456 | 62nd |
Source: SEC filing on August 5, 2022.
Mahadevia's colleagues
We found one more compensation record of an executive who worked with Ankit Mahadevia at Spero Therapeutics in 2020.
2020
Cristina Larkin
Spero Therapeutics
Chief Operating Officer
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019